Anti-CDK6 Antibody, clone 2J3 ZooMAb® Rabbit Monoclonal

enhanced validationgreener alternative

recombinant, expressed in HEK 293 cells

Cyclin-dependent kinase 6, Cell division protein kinase 6, Serine/threonine-protein kinase PLSTIR

biological source

rabbit (recombinant)


expressed in HEK 293 cells

antibody form

purified antibody

antibody product type

primary antibodies


2J3, monoclonal
recombinant monoclonal

product line

ZooMAb® learn more



mol wt

calculated mol wt 36.94 kDa
observed mol wt 37 kDa

species reactivity

rat, mouse, human


antibody small pack of 25 μL

greener alternative product characteristics

Waste Prevention
Designing Safer Chemicals
Design for Energy Efficiency
Learn more about the Principles of Green Chemistry.

enhanced validation

recombinant expression
Learn more about Antibody Enhanced Validation


affinity binding assay: suitable
immunocytochemistry: suitable
immunohistochemistry (formalin-fixed, paraffin-embedded sections): suitable
western blot: suitable





greener alternative category


shipped in


storage temp.


General description

ZooMAb antibodies represent an entirely new generation of recombinant monoclonal antibodies.

Each ZooMAb antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb antibodies are reliably available and ready to ship when you need them.

Learn more about ZooMAb here.


Clone 2J3 is a ZooMAb rabbit recombinant monoclonal antibody that specifically detects CDK6. It targets an epitope within 21 amino acids from the C-terminal region.


KLH-conjugated linear peptide corresponding to 21 amino acids from the C-terminal region of human CDK6.


Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected CDK6 in HeLa cell lysate.

Affinity Binding Assay: A representative lot of this antibody bound CDK6 peptide with a KD value of 2.8 x 10-6 in an affinity binding assay.

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected CDK6 in HeLa, A431, HUVEC, and NIH 3T3 cells.

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected CDK6 in human kidney and human testis tissue sections.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user
Anti-CDK6, clone 2J3 ZooMAb, Cat. No. ZRB1490, is a recombinant Rabbit monoclonal antibody that specifically targets CDK6 and is tested for use in Affinity Binding Assay, Immunocytochemistry, Immunohistochemistry (Paraffin), Western Blotting.

Target description

DNA polymerase beta (UniProt: P06746; also known as EC:, DNAP, Polβ, DNA pol beta) is encoded by the POLB gene (Gene ID: 5423) in human. Pol β is a member of the X family of DNA polymerases. It plays a role in the base excision repair pathway that is essential to cleanse the genome of simple base lesions and abasic sites that arise in DNA from spontaneous base loss. Polβ is cytoplasmic under normal conditions, but it translocates to the nucleus following DNA damage where it associates with AP endonuclease 1 (Apex) to carry out DNA repair. It possesses two catalytic activities: DNA polymerase activity and dRP lyase activity. The active site for each of these activities is located on a distinct domain of the protein: 31 kDa polymerase domain and amino-terminal 8 kDa lyase domain. Polβ does not have proofreading activity; however, its accuracy in vitro results exclusively from the nucleotide selectivity of this enzyme. Aberrant Polβ overexpression results in an increased rate of spontaneous mutagenesis and a highly mutagenic tolerance phenotype and about thirty percent of all tumors are reported to harbor mutations in the POLB gene. This ZooMAb recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Beard WA., et al. (2006). Methods Enzymol. 408; 91-107).

Physical form

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.


0.3 mg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Storage and Stability

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Legal Information

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany


Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

WGK Germany


Certificate of Analysis

Certificate of Origin

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.